摘要
目的探讨3R在肿瘤药物筛选上应用的可行性。方法(1)给KM小鼠接种S180、EAC、H22三株肿瘤,建立“一体三瘤”模型;(2)分别给KM小鼠接种S180或EAC或H22建立“一体单瘤”模型。给三瘤模型小鼠和单瘤模型小鼠口服待筛选的药物,观察药物对两种模型小鼠的抑瘤率以及其机体免疫功能的影响。结果(1)三瘤模型小鼠的各种瘤株与单瘤模型的相同瘤株相比,瘤体的生长缓慢。但没有影响对药物抑制肿瘤结果的判断。(2)三瘤模型和单瘤模型在小鼠的胸腺、脾以及DTH、廓清指数K、吞噬指数α等免疫参数上比较接近。结论“三瘤”模型小鼠可以用于肿瘤药物筛选中的抑瘤率和免疫功能实验。
Objective To investigate the possibility to use 3R （replacement, reduction, refinement） method in antitumor drug screening. Methods （ 1 ） The KM mice were inoculated with S180, H22 and EAC tumors to establish “three-tumors in one” model; （2） 1/3 KM mice were inoculated with S180 , 1/3 KM mice were inoculated with H22 , the others were inoculated with EAC, to establish “one-tumor in one”model. The “three-tumors in one”model and the “one-tumor in one” model mice were infused with the anti-tumor drug per os, to observe the effect on the ratio of tumor inhibition and immune function. Results （ 1 ） The tumor growed slower in the “three-tumors in one” model mice than in “one-tumor in one” model, but there was no influence on the judgment of the drug＇s tumor-inhibition function. （2） The “three-tumors in one” model was very close to the “one- tumor in one” model in immunological parameter such as thymus, spleen, DTH, phagocytic and clearing indices. Conchlsion The “three-tumors in one” model can he used to tumor inhibition and immune function experiments of the anti-tumor drug screening.
出处
《中国比较医学杂志》
CAS
2005年第6期375-378,共4页
Chinese Journal of Comparative Medicine
关键词
3R
抑瘤率
药物评价
临床前
免疫
3R
Ratio of tumor inhibition
Drug evaluation, preelinieal
Immunological parameter
